Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
Earnings releases

Latest results release: Nov 9, 2026

8-K item 2.02, exhibit 99

What ROIV's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 9, 2026 · EX-99.1

Roivant Reports Financial Results for the Second Quarter Ended September 30,

Open on SEC

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update • LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026

• IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA); FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA

• Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis (NIU); sNDA submission for NIU expected in the first half of calendar year 2027

• Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease (PH-ILD); Phase 3 PHrontier study initiated

• In light of the evolving Sjögren’s disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial

• Roivant reported consolidated cash, cash equivalents and marketable securities of $4.2 billion as of September 30, 2026, including the cash payment received from Moderna in July, supporting cash runway into profitability

• Roivant will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update

• Roivant will also host an Investor Day in New York City and virtually on December 9, 2026

BASEL, Switzerland and LONDON and NEW YORK, November 9, 2026 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2026, and provided a business update.

“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand,” said Matt Gline, CEO of Roivant. “It has also been an exciting quarter in terms of progress in the clinic. Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options. This builds on what was already an incredible quarter in terms of delivery for patients, with phenomenal data both in our brepocitinib Phase 3 studies in NIU as well as our Phase 2 study of mosliciguat in PH-ILD. I couldn’t be happier with the execution of our team in every domain.”

: LISRAYA became commercially available in the U.S. in August 2026 and generated net product revenue of $31.0 million in its first 5 weeks of launch.

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials comprising the CLARITY program in NIU. Median time to treatment failure for brepocitinib patients was greater than 48 weeks in both studies, compared with ~12 weeks on placebo in each study (p<0.0001 in both studies), including 40 weeks of steroid-free treatment, setting a new bar for time to failure and steroid-sparing benefit in NIU. Pooled across the CLARITY studies, 62% of patients on brepocitinib achieved steroid-free quiescence at Week 48, compared with 20% on placebo (p<0.0001), with similar results in each study. Of patients that entered the CLARITY studies (pooled) with macular edema, 42% of eyes on brepocitinib achieved resolution of macular edema at Week 48, compared with 4.8% on placebo (p<0.0001), with similar results in each study. The magnitude and breadth of benefit observed across every ranked endpoint, compared with results reported in registrational

trials of existing NIU therapies, suggest brepocitinib has the potential to be the most effective systemic, non-steroid treatment option for NIU. Safety data consistent with prior brepocitinib clinical trials; no new safety signals or findings. Priovant intends to file a supplemental New Drug Application (sNDA) for brepocitinib for the treatment of NIU in the first half of calendar year 2027.

Additionally, the Phase 3 study in cutaneous sarcoidosis (CS) and Phase 2b/3 study in lichen planopilaris (LPP) are progressing well.

: Following the open-label lead-in in Period 1 of the potentially registrational trial in patients with D2T RA, where a total of 170 participants were enrolled to receive IMVT-1402 600 mg for 16 weeks, study participants meeting the criteria for an ACR20 response at Weeks 14 and 16 were eligible to advance to Period 2 of the trial. A total of 117 participants were included in the Period 2 efficacy analysis and randomized to IMVT-1402 600 mg (n=40), IMVT-1402 300 mg (n=36), or placebo (n=41). IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139). Participants randomized to IMVT-1402 300 mg did not show a difference from placebo, with 75.0% maintaining an ACR20 response at Week 28 (p=0.9426). The secondary endpoints, change in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) from Period 2 baseline to Week 28, numerically favored IMVT-1402 600 mg over placebo (p=0.1096 and p=0.1299, respectively). In exploratory analyses, ACR50 response rates at Week 28 were 80.0% for IMVT-1402 600 mg vs. 56.1% for placebo (nominal p=0.0117), and ACR70 response rates were 52.5% vs. 36.6% (nominal p=0.1674); the trial was not powered to detect differences in these measures. IMVT-1402 was generally well tolerated in Period 2, with no serious adverse events, Grade 3 or higher treatment-emergent adverse events, or adverse events leading to treatment discontinuation reported in any arm. FDA discussions are planned for later this year to determine the path forward for the registrational program of IMVT-1402 in D2T RA.

In light of the evolving SjD landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial.

IMVT-1402 clinical development timelines remain on track across the potentially registrational trials in Graves’ disease (GD), myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

: Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in PH-ILD; the study met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial. The study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (-357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP, p=0.0002), both clinically meaningful and statistically significant. Pre-specified exploratory Week 24 results showed continued placebo-adjusted improvements in 6MWD to +52.7m (nominal p<0.0001) and NT-proBNP to -75.9% (-487.1 pg/mL, nominal p<0.0001). Mosliciguat was observed to be well tolerated with a favorable safety profile, and compared with placebo, a lower proportion of patients experienced cough (12.1% mosliciguat vs. 18.2% placebo), a common tolerability challenge with inhaled prostacyclins.

The Phase 3 PHrontier study of mosliciguat in patients with PH-ILD has been initiated, with enrollment underway.

: In July 2026, Genevant Sciences GmbH (Genevant) and Arbutus received $950 million from Moderna, the initial payment under the global $2.25 billion patent infringement settlement. Oral arguments on Moderna’s Section 1498 appeal took place on November 5, 2026.

: Roivant reported consolidated cash, cash equivalents and marketable securities of $4.2 billion as of September 30, 2026, including the cash payment received from Moderna in July, supporting cash runway into profitability. For the three months ended September 30, 2026, Roivant repurchased 2.1 million common shares for an aggregate repurchase price of approximately $72.5 million.

intends to file an sNDA for brepocitinib for the treatment of NIU in the first half of calendar year 2027 and expects topline data from the Phase 3 study in CS in calendar year 2028. Roivant continues to actively explore other indications for brepocitinib.

plans to meet with the FDA later this year to determine the path forward for the registrational program of IMVT-1402 in D2T RA. Immunovant expects to report topline data across potentially registrational trials of IMVT-1402 in GD and MG in calendar year 2027. In calendar year 2028, topline data are expected for the potentially registrational trial of IMVT-1402 in CIDP.

Phase 3 PHrontier study of mosliciguat and Phase 2 PHactor study of mosliciguat in combination with inhaled treprostinil in PH-ILD are ongoing. Roivant continues to actively explore other indications for mosliciguat.

LNP litigation continues to progress. An additional $1.3 billion payment under the Moderna settlement is contingent upon a resolution of Moderna’s Section 1498 appeal favorable to Genevant and Arbutus. The Pfizer/BioNTech case is ongoing.

As of September 30, 2026, the Company had consolidated cash, cash equivalents, and marketable securities of $4.2 billion.

Product revenue, net was $31.0 million for the three months ended September 30, 2026, consisting of net product revenue from sales of LISRAYA in its first 5 weeks of launch following FDA approval in August 2026. We did not have product revenue for the three months ended September 30, 2025.

Research and development (R&D) expenses decreased by $18.8 million to $145.7 million for the three months ended September 30, 2026, compared to $164.6 million for the three months ended September 30, 2025. This decrease was primarily driven by decreases in personnel-related expense of $7.4 million, program-specific costs of $6.4 million and share-based compensation of $3.0 million.

The decrease of $6.4 million in program-specific costs was primarily driven by a decrease of $18.3 million related to the anti-FcRn franchise. This decrease reflected lower costs for the IMVT-1402 study in cutaneous lupus erythematosus, which was discontinued in September 2026, the wind-down of batoclimab clinical trials and the timing of contract manufacturing costs. These decreases were partially offset by higher costs for ongoing clinical trials of IMVT-1402 in Graves’ disease, and further offset by an increase of $11.6 million related to mosliciguat, reflecting the progression of the program.

The majority of share-based compensation and personnel-related expenses, which are unallocated internal costs, were related to the anti-FcRn franchise activities at Immunovant during the three months ended September 30, 2026 and 2025. The decreases in Immunovant’s share-based compensation and personnel- related expenses compared to the same period in 2025 primarily resulted from lower headcount.

Adjusted R&D expenses (Non-GAAP) were $137.4 million for the three months ended September 30, 2026, compared to $152.9 million for the three months ended September 30, 2025.

Selling, general and administrative (SG&A) expenses increased by $11.0 million to $154.1 million for the three months ended September 30, 2026, compared to $143.1 million for the three months ended September 30, 2025. This increase was primarily due to higher selling, general and administrative expenses as a result of the commercial launch of LISRAYA. This was partially offset by a decrease of $11.2 million due to expense recognized for one-time cash retention awards from the Senior Executive Compensation Program during the three months ended September 30, 2025.

Adjusted SG&A expenses (Non-GAAP) were $82.5 million for the three months ended September 30, 2026, compared to $72.1 million for the three months ended September 30, 2025.

Loss from continuing operations, net of tax was $153.0 million for the three months ended September 30, 2026, compared to $166.0 million for the three months ended September 30, 2025. On a basic and diluted per share basis, loss from continuing operations, net of tax was $0.29 and $0.17 for the three months ended September 30, 2026 and 2025 , respectively. Adjusted loss from continuing operations, net of tax (Non-GAAP) was $133.4 million for the three months ended September 30, 2026, compared to $187.8 million for the three months ended September 30, 2025.

Net loss attributable to Roivant was $191.6 million for the three months ended September 30, 2026, compared to $113.5 million for the three months ended September 30, 2025. On a basic and diluted per share basis, net loss attributable to Roivant was $0.27 and $0.17 for the three months ended September 30, 2026 and 2025 , respectively. Net loss attributable to Roivant during the three months ended September 30, 2026 includes $95.9 million related to the distributions on outstanding restricted stock units and options of Genevant Sciences Ltd., Genevant ’ s parent, which participated through dividend- equivalent rights in the distribution of Moderna settlement proceeds. These distributions increased both basic and diluted net loss per common share by $0.13 for the period.

(3) As a result of the global settlement with Moderna entered in March 2026, the Company recognized a gain during the year ended March 31, 2026 for Genevant’s expected portion of a non-contingent, non-creditable and non-refundable

payment. The Company recognized an additional gain during the six months ended September 30, 2026, reflecting the final determination of actual litigation costs incurred.

(4) Represents the unrealized gains on equity investments in unconsolidated entities that are accounted for at fair value with changes in value reported in earnings.

(5) Represents the change in fair value of liability instruments, which is non- cash and primarily includes the loss relating to the measurement and recognition of fair value on a recurring basis of certain liabilities.

Roivant will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.

To access the conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

Roivant will also host an investor day on Wednesday, December 9, 2026. To attend the event in person or by webcast, please register online using this registration link.

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward- looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, the timing of potential regulatory approvals for our product and product candidates, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
  Roivant Reports Financial Results for the Second Quarter Ended September 30,  
                       2026, and Provides Business Update                       
• LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its
first 5 weeks of launch following FDA approval in August 2026

• IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5%
vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following
open-label lead-in) of the potentially registrational trial in patients with
difficult-to-treat rheumatoid arthritis (D2T RA); FDA discussions planned for
later this year to determine the path forward regarding the registrational
program for IMVT-1402 in D2T RA

• Brepocitinib met the primary and all key secondary endpoints in the Phase 3
CLARITY-1 and CLARITY-2 trials in non-infectious uveitis (NIU); sNDA submission
for NIU expected in the first half of calendar year 2027

• Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in
pulmonary hypertension associated with interstitial lung disease (PH-ILD); Phase
3 PHrontier study initiated

• In light of the evolving Sjögren’s disease (SjD) landscape and recent data in
the field, we expect it is unlikely that we will advance IMVT-1402 further in
SjD beyond the ongoing, fully enrolled Phase 2 trial

• Roivant reported consolidated cash, cash equivalents and marketable securities
of $4.2 billion as of September 30, 2026, including the cash payment received
from Moderna in July, supporting cash runway into profitability

• Roivant will host a live conference call and webcast at 8:00 a.m. ET on
Monday, November 9, 2026, to report its financial results for the second quarter
ended September 30, 2026, and provide a business update

• Roivant will also host an Investor Day in New York City and virtually on
December 9, 2026

BASEL, Switzerland and LONDON and NEW YORK, November 9, 2026 – Roivant (Nasdaq:
ROIV) today reported its financial results for the second quarter ended
September 30, 2026, and provided a business update.

“This quarter has marked a major transition for Roivant. LISRAYA is now
commercially available to patients and we are off to a strong start, with $31.0
million in net product revenue in the first 5 weeks of launch – reflecting
strong early patient and prescriber demand,” said Matt Gline, CEO of Roivant.
“It has also been an exciting quarter in terms of progress in the clinic. Today
we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in
difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose
met the primary endpoint in Period 2, and the broader data support its potential
to maintain and deepen responses in patients who have failed multiple advanced
therapies and who are in need of new options. This builds on what was already an
incredible quarter in terms of delivery for patients, with phenomenal data both
in our brepocitinib Phase 3 studies in NIU as well as our Phase 2 study of
mosliciguat in PH-ILD. I couldn’t be happier with the execution of our team in
every domain.”
                                                                                
  Recent Developments                                                           
                                                                                
•
                                                                                
  Priovant                                                                      
                                                                                
: LISRAYA became commercially available in the U.S. in August 2026 and generated
net product revenue of $31.0 million in its first 5 weeks of launch.

Brepocitinib 45 mg once-daily achieved statistically significant benefit
compared to placebo on the primary and all key secondary endpoints for each of
CLARITY-1 and CLARITY-2, the two identical Phase 3 trials comprising the CLARITY
program in NIU. Median time to treatment failure for brepocitinib patients was
greater than 48 weeks in both studies, compared with ~12 weeks on placebo in
each study (p<0.0001 in both studies), including 40 weeks of steroid-free
treatment, setting a new bar for time to failure and steroid-sparing benefit in
NIU. Pooled across the CLARITY studies, 62% of patients on brepocitinib achieved
steroid-free quiescence at Week 48, compared with 20% on placebo (p<0.0001),
with similar results in each study. Of patients that entered the CLARITY studies
(pooled) with macular edema, 42% of eyes on brepocitinib achieved resolution of
macular edema at Week 48, compared with 4.8% on placebo (p<0.0001), with similar
results in each study. The magnitude and breadth of benefit observed across
every ranked endpoint, compared with results reported in registrational

trials of existing NIU therapies, suggest brepocitinib has the potential to be
the most effective systemic, non-steroid treatment option for NIU. Safety data
consistent with prior brepocitinib clinical trials; no new safety signals or
findings. Priovant intends to file a supplemental New Drug Application (sNDA)
for brepocitinib for the treatment of NIU in the first half of calendar year
2027.

Additionally, the Phase 3 study in cutaneous sarcoidosis (CS) and Phase 2b/3
study in lichen planopilaris (LPP) are progressing well.

•
                                                                                
  Immunovant                                                                    
                                                                                
: Following the open-label lead-in in Period 1 of the potentially registrational
trial in patients with D2T RA, where a total of 170 participants were enrolled
to receive IMVT-1402 600 mg for 16 weeks, study participants meeting the
criteria for an ACR20 response at Weeks 14 and 16 were eligible to advance to
Period 2 of the trial. A total of 117 participants were included in the Period 2
efficacy analysis and randomized to IMVT-1402 600 mg (n=40), IMVT-1402 300 mg
(n=36), or placebo (n=41). IMVT-1402 600 mg met the primary endpoint of ACR20
response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139). Participants randomized
to IMVT-1402 300 mg did not show a difference from placebo, with 75.0%
maintaining an ACR20 response at Week 28 (p=0.9426). The secondary endpoints,
change in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity
Index (SDAI) from Period 2 baseline to Week 28, numerically favored IMVT-1402
600 mg over placebo (p=0.1096 and p=0.1299, respectively). In exploratory
analyses, ACR50 response rates at Week 28 were 80.0% for IMVT-1402 600 mg vs.
56.1% for placebo (nominal p=0.0117), and ACR70 response rates were 52.5% vs.
36.6% (nominal p=0.1674); the trial was not powered to detect differences in
these measures. IMVT-1402 was generally well tolerated in Period 2, with no
serious adverse events, Grade 3 or higher treatment-emergent adverse events, or
adverse events leading to treatment discontinuation reported in any arm. FDA
discussions are planned for later this year to determine the path forward for
the registrational program of IMVT-1402 in D2T RA.

In light of the evolving SjD landscape and recent data in the field, we expect
it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing,
fully enrolled Phase 2 trial.

IMVT-1402 clinical development timelines remain on track across the potentially
registrational trials in Graves’ disease (GD), myasthenia gravis (MG) and
chronic inflammatory demyelinating polyneuropathy (CIDP).

•
                                                                                
  Pulmovant                                                                     
                                                                                
: Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in
PH-ILD; the study met its primary endpoint, demonstrating a clinically
meaningful and statistically significant placebo-adjusted reduction in pulmonary
vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever
reported PVR reduction in any randomized controlled PH trial. The study also met
its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted
improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (-357.7
pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide
(NT-proBNP, p=0.0002), both clinically meaningful and statistically significant.
Pre-specified exploratory Week 24 results showed continued placebo-adjusted
improvements in 6MWD to +52.7m (nominal p<0.0001) and NT-proBNP to -75.9%
(-487.1 pg/mL, nominal p<0.0001). Mosliciguat was observed to be well tolerated
with a favorable safety profile, and compared with placebo, a lower proportion
of patients experienced cough (12.1% mosliciguat vs. 18.2% placebo), a common
tolerability challenge with inhaled prostacyclins.

The Phase 3 PHrontier study of mosliciguat in patients with PH-ILD has been
initiated, with enrollment underway.

•
                                                                                
  Genevant                                                                      
                                                                                
: In July 2026, Genevant Sciences GmbH (Genevant) and Arbutus received $950
million from Moderna, the initial payment under the global $2.25 billion patent
infringement settlement. Oral arguments on Moderna’s Section 1498 appeal took
place on November 5, 2026.

•
                                                                                
  Roivant                                                                       
                                                                                
: Roivant reported consolidated cash, cash equivalents and marketable securities
of $4.2 billion as of September 30, 2026, including the cash payment received
from Moderna in July, supporting cash runway into profitability. For the three
months ended September 30, 2026, Roivant repurchased 2.1 million common shares
for an aggregate repurchase price of approximately $72.5 million.
                                                                                
  Major Upcoming Milestones                                                     
                                                                                
•
                                                                                
  Priovant                                                                      
                                                                                
intends to file an sNDA for brepocitinib for the treatment of NIU in the first
half of calendar year 2027 and expects topline data from the Phase 3 study in CS
in calendar year 2028. Roivant continues to actively explore other indications
for brepocitinib.

•
                                                                                
  Immunovant                                                                    
                                                                                
plans to meet with the FDA later this year to determine the path forward for the
registrational program of IMVT-1402 in D2T RA. Immunovant expects to report
topline data across potentially registrational trials of IMVT-1402 in GD and MG
in calendar year 2027. In calendar year 2028, topline data are expected for the
potentially registrational trial of IMVT-1402 in CIDP.

•
                                                                                
  Pulmovant                                                                     
                                                                                
Phase 3 PHrontier study of mosliciguat and Phase 2 PHactor study of mosliciguat
in combination with inhaled treprostinil in PH-ILD are ongoing. Roivant
continues to actively explore other indications for mosliciguat.

•
                                                                                
  Genevant                                                                      
                                                                                
LNP litigation continues to progress. An additional $1.3 billion payment under
the Moderna settlement is contingent upon a resolution of Moderna’s Section 1498
appeal favorable to Genevant and Arbutus. The Pfizer/BioNTech case is ongoing.

Second Quarter Ended September 30, 2026 Financial Summary
                                                                                
  Cash Position and Marketable Securities                                       
                                                                                
As of September 30, 2026, the Company had consolidated cash, cash equivalents,
and marketable securities of $4.2 billion.
                                                                                
  Product Revenue, Net                                                          
                                                                                
Product revenue, net was $31.0 million for the three months ended September 30,
2026, consisting of net product revenue from sales of LISRAYA in its first 5
weeks of launch following FDA approval in August 2026. We did not have product
revenue for the three months ended September 30, 2025.
                                                                                
  Research and Development Expenses                                             
                                                                                
Research and development (R&D) expenses decreased by $18.8 million to $145.7
million for the three months ended September 30, 2026, compared to $164.6
million for the three months ended September 30, 2025. This decrease was
primarily driven by decreases in personnel-related expense of $7.4 million,
program-specific costs of $6.4 million and share-based compensation of $3.0
million.

The decrease of $6.4 million in program-specific costs was primarily driven by a
decrease of $18.3 million related to the anti-FcRn franchise. This decrease
reflected lower costs for the IMVT-1402 study in cutaneous lupus erythematosus,
which was discontinued in September 2026, the wind-down of batoclimab clinical
trials and the timing of contract manufacturing costs. These decreases were
partially offset by higher costs for ongoing clinical trials of IMVT-1402 in
Graves’ disease, and further offset by an increase of $11.6 million related to
mosliciguat, reflecting the progression of the program.

The majority of share-based compensation and personnel-related expenses, which
are unallocated internal costs, were related to the anti-FcRn franchise
activities at Immunovant during the three months ended September 30, 2026 and
2025. The decreases in Immunovant’s share-based compensation and personnel-
related expenses compared to the same period in 2025 primarily resulted from
lower headcount.

Adjusted R&D expenses (Non-GAAP) were $137.4 million for the three months ended
September 30, 2026, compared to $152.9 million for the three months ended
September 30, 2025.
                                                                                
  Selling, General and Administrative Expenses                                  
                                                                                
Selling, general and administrative (SG&A) expenses increased by $11.0 million
to $154.1 million for the three months ended September 30, 2026, compared to
$143.1 million for the three months ended September 30, 2025. This increase was
primarily due to higher selling, general and administrative expenses as a result
of the commercial launch of LISRAYA. This was partially offset by a decrease of
$11.2 million due to expense recognized for one-time cash retention awards from
the Senior Executive Compensation Program during the three months ended
September 30, 2025.

Adjusted SG&A expenses (Non-GAAP) were $82.5 million for the three months ended
September 30, 2026, compared to $72.1 million for the three months ended
September 30, 2025.
                                                                                
  Loss from continuing operations, net of tax                                   
                                                                                
Loss from continuing operations, net of tax was $153.0 million for the three
months ended September 30, 2026, compared to $166.0 million for the three months
ended September 30, 2025. On a basic and diluted per share basis, loss from
continuing operations, net of tax was $0.29 and $0.17 for the three months ended
September 30, 2026 and 2025 , respectively. Adjusted loss from continuing
operations, net of tax (Non-GAAP) was $133.4 million for the three months ended
September 30, 2026, compared to $187.8 million for the three months ended
September 30, 2025.
                                                                                
  Net loss attributable to Roivant Sciences Ltd.                                
                                                                                
Net loss attributable to Roivant was $191.6 million for the three months ended
September 30, 2026, compared to $113.5 million for the three months ended
September 30, 2025. On a basic and diluted per share basis, net loss
attributable to Roivant was $0.27 and $0.17 for the three months ended September
30, 2026 and 2025 , respectively. Net loss attributable to Roivant during the
three months ended September 30, 2026 includes $95.9 million related to the
distributions on outstanding restricted stock units and options of Genevant
Sciences Ltd., Genevant ’ s parent, which participated through dividend-
equivalent rights in the distribution of Moderna settlement proceeds. These
distributions increased both basic and diluted net loss per common share by
$0.13 for the period.
                                                                                
                             ROIVANT SCIENCES LTD.                              
                                                                                
                                                                                
                          Selected Balance Sheet Data                           
                                                                                
                           (unaudited, in thousands)                            
                                                                                
                                       September 30, 2026       March 31, 2026  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents         $           1,642,266    $       1,419,232  
  Marketable securities                         2,565,320            2,872,601  
  Litigation settlement                                 —              770,235  
  receivable                                                                    
  Total assets                                  4,975,824            5,708,687  
  Total liabilities                               380,104              416,275  
  Total shareholders’ equity                    4,595,720            5,292,412  
  Total liabilities and                                                         
  shareholders’                                 4,975,824            5,708,687  
  equity                                                                        
                                                                                
                                                                                
                             ROIVANT SCIENCES LTD.                              
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
         (unaudited, in thousands, except share and per share amounts)          
                                                                                
           Three                               Six                              
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
           30,                                 30,                              
  Reve…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Prod…                                                                         
  reve…    $        30,969    $           —    $        30,969    $          —  
  net                                                                           
  Lice…                                                                         
  mile…                                                                         
  and                4,152            1,571              5,594           3,741  
  other                                                                         
  reve…                                                                         
  Reve…             35,121            1,571             36,563           3,741  
  net                                                                           
  Oper…                                                                         
  expe…                                                                         
  Cost                                                                          
  of                 3,347              111              3,631             265  
  reve…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…                                                                         
  (inc…                                                                         
  $7,9…                                                                         
  and                                                                           
  $10,…                                                                         
  of                                                                            
  shar…                                                                         
  comp…                                                                         
  expe…                                                                         
  for                                                                           
  the                                                                           
  three                                                                         
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,               145,7…          164,568            347,763          317,4…  
  2026                                                                          
  and                                                                           
  2025                                                                          
  and                                                                           
  $16,…                                                                         
  and                                                                           
  $22,…                                                                         
  for                                                                           
  the                                                                           
  six                                                                           
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                          
  and                                                                           
  2025,                                                                         
  resp…                                                                         
  Sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
  (inc…                                                                         
  $71,…                                                                         
  and                                                                           
  $70,…                                                                         
  of                                                                            
  shar…                                                                         
  comp…                                                                         
  expe…                                                                         
  for                                                                           
  the                                                                           
  three                                                                         
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,               154,0…          143,125            319,603          277,1…  
  2026                                                                          
  and                                                                           
  2025                                                                          
  and                                                                           
  $145…                                                                         
  and                                                                           
  $141…                                                                         
  for                                                                           
  the                                                                           
  six                                                                           
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                          
  and                                                                           
  2025,                                                                         
  resp…                                                                         
  Total                                                                         
  oper…             303,1…          307,804            670,997          594,8…  
  expe…                                                                         
  Gain                                                                          
  on                     —                —                392               —  
  liti…                                                                         
  sett…                                                                         
  Loss                                                                          
  from              -268,…          -306,2…            -634,0…          -591,…  
  oper…                                                                         
  Chan…                                                                         
  in                                                                            
  fair              -60,2…          -128,5…            -96,929          -109,…  
  value                                                                         
  of                                                                            
  inve…                                                                         
  Chan…                                                                         
  in                                                                            
  fair                                                                          
  value                  —           20,959                  —          23,288  
  of                                                                            
  liab…                                                                         
  inst…                                                                         
  Inte…             -41,6…          -45,341            -78,534          -93,6…  
  inco…                                                                         
  Other                                                                         
  expe…                200            5,694              2,330          16,902  
  net                                                                           
  Loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…             -166,…          -159,0…            -460,9…          -428,…  
  befo…                                                                         
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax               -13,3…            6,995            -17,329          11,644  
  (ben…                                                                         
  expe…                                                                         
  Loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…             -152,…          -166,0…            -443,5…          -439,…  
  net                                                                           
  of                                                                            
  tax                                                                           
  Inco…                                                                         
  from                                                                          
  disc…                                                                         
  oper…             15,763                —             15,763               —  
  net                                                                           
  of                                                                            
  tax                                                                           
  Net               -137,…          -166,0…            -427,8…          -439,…  
  loss                                                                          
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…             54,408          -52,520            -46,361          -103,…  
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  Net                                                                           
  loss                                                                          
  attr…                                                                         
  to       $        -191,…    $     -113,5…    $       -381,4…    $     -336,…  
  Roiv…                                                                         
  Scie…                                                                         
  Ltd.                                                                          
  Amou…                                                                         
  attr…                                                                         
  to                                                                            
  Roiv…                                                                         
  Scie…                                                                         
  Ltd.:                                                                         
  Loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…    $        -207,…    $     -113,5…    $       -397,2…    $     -336,…  
  net                                                                           
  of                                                                            
  tax                                                                           
  Inco…                                                                         
  from                                                                          
  disc…                                                                         
  oper…             15,763                —             15,763               —  
  net                                                                           
  of                                                                            
  tax                                                                           
  Net                                                                           
  loss                                                                          
  attr…                                                                         
  to       $        -191,…    $     -113,5…    $       -381,4…    $     -336,…  
  Roiv…                                                                         
  Scie…                                                                         
  Ltd.                                                                          
  Basic                                                                         
  and                                                                           
  dilu…                                                                         
  net                                                                           
  loss                                                                          
  per                                                                           
  comm…                                                                         
  shar…                                                                         
  Loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…    $         -0.29    $       -0.17    $         -0.55    $      -0.49  
  net                                                                           
  of                                                                            
  tax                                                                           
  Inco…                                                                         
  from                                                                          
  disc…                                                                         
  oper…    $          0.02    $           —    $          0.02    $          —  
  net                                                                           
  of                                                                            
  tax                                                                           
  Net                                                                           
  loss                                                                          
  per                                                                           
  comm…    $         -0.27    $       -0.17    $         -0.53    $      -0.49  
  shar…                                                                         
  and                                                                           
  dilu…                                                                         
  Weig…                                                                         
  aver…                                                                         
  shar…             722,7…          680,94…            721,76…          680,6…  
  outs…                                                                         
  and                                                                           
  dilu…                                                                         
                                                                                
                                                                                
                             ROIVANT SCIENCES LTD.                              
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                           (unaudited, in thousands)                            
                                                                                
                          Three                             Six                 
                         Months                          Months                 
                          Ended                           Ended                 
                         Septe…                          Septe…                 
           Note    2026     30,    2025            2026     30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…            $     -152,…    $     -166,…    $     -443,…    $     -439…  
  net                                                                           
  of                                                                            
  tax                                                                           
  Adju…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…                                                                         
  Shar…      -1           7,965          10,996          16,686          22,0…  
  comp…                                                                         
  Depr…                                                                         
  and        -2             347             676             693          1,462  
  amor…                                                                         
  Sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
  Shar…      -1          71,332          70,825          145,9…          141,…  
  comp…                                                                         
  Depr…                                                                         
  and        -2             257             246             511            558  
  amor…                                                                         
  Gain                                                                          
  on         -3               —               —            -392              —  
  liti…                                                                         
  sett…                                                                         
  Othe…                                                                         
  Chan…                                                                         
  in                                                                            
  fair       -4          -60,2…          -128,…          -96,9…          -109…  
  value                                                                         
  of                                                                            
  inve…                                                                         
  Chan…                                                                         
  in                                                                            
  fair                                                                          
  value      -5               —          20,959               —          23,2…  
  of                                                                            
  liab…                                                                         
  inst…                                                                         
  Esti…                                                                         
  inco…                                                                         
  tax        -6               —           3,059               —          2,116  
  impa…                                                                         
  from                                                                          
  adju…                                                                         
  Adju…                                                                         
  loss                                                                          
  from                                                                          
  cont…                                                                         
  oper…            $     -133,…    $     -187,…    $     -377,…    $     -357…  
  net                                                                           
  of                                                                            
  tax                                                                           
  (Non…                                                                         
                                                                                
                                                                                
                          Three                            Six                  
                         Months                          Mont…                  
                          Ended                          Ended                  
                         Septe…                          Sept…                  
           Note    2026     30,    2025            2026    30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Rese…                                                                         
  and              $     145,7…    $     164,5…    $     347,…    $     317,4…  
  deve…                                                                         
  expe…                                                                         
  Adju…                                                                         
  Shar…      -1           7,965          10,996          16,6…          22,095  
  comp…                                                                         
  Depr…                                                                         
  and        -2             347             676            693           1,462  
  amor…                                                                         
  Adju…                                                                         
  rese…                                                                         
  and              $     137,4…    $     152,8…    $     330,…    $     293,9…  
  deve…                                                                         
  expe…                                                                         
  (Non…                                                                         
                                                                                
                                                                                
                          Three                            Six                  
                         Months                          Mont…                  
                          Ended                          Ended                  
                         Septe…                          Sept…                  
           Note    2026     30,    2025            2026    30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Sell…                                                                         
  gene…                                                                         
  and              $     154,0…    $     143,1…    $     319,…    $     277,1…  
  admi…                                                                         
  expe…                                                                         
  Adju…                                                                         
  Shar…      -1          71,332          70,825          145,…          141,9…  
  comp…                                                                         
  Depr…                                                                         
  and        -2             257             246            511             558  
  amor…                                                                         
  Adju…                                                                         
  sell…                                                                         
  gene…                                                                         
  and              $     82,487    $     72,054    $     173,…    $     134,6…  
  admi…                                                                         
  expe…                                                                         
  (Non…                                                                         
                                                                                
Notes to non-GAAP financial measures:

(1) Represents non-cash share-based compensation expense.

(2) Represents non-cash depreciation and amortization expense.

(3) As a result of the global settlement with Moderna entered in March 2026, the
Company recognized a gain during the year ended March 31, 2026 for Genevant’s
expected portion of a non-contingent, non-creditable and non-refundable

payment. The Company recognized an additional gain during the six months ended
September 30, 2026, reflecting the final determination of actual litigation
costs incurred.

(4) Represents the unrealized gains on equity investments in unconsolidated
entities that are accounted for at fair value with changes in value reported in
earnings.

(5) Represents the change in fair value of liability instruments, which is non-
cash and primarily includes the loss relating to the measurement and recognition
of fair value on a recurring basis of certain liabilities.

(6) Represents the estimated tax effect of the adjustments.
                                                                                
  Investor Conference Call Information                                          
                                                                                
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Monday,
November 9, 2026, to report its financial results for the second quarter ended
September 30, 2026, and provide a business update.

To access the conference call by phone, please register online using this
registration link . The presentation and webcast details will also be available
under “Events & Presentations” in the Investors section of the Roivant website
at https://investor.roivant.com/news-events/events. The archived webcast will be
available on Roivant’s website after the conference call.

Roivant will also host an investor day on Wednesday, December 9, 2026. To attend
the event in person or by webcast, please register online using this
registration link.
                                                                                
  About Roivant                                                                 
                                                                                
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims
to improve the lives of patients by accelerating the development and
commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™
(brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved
for the treatment of dermatomyositis in adult patients and also in late-stage
development for the treatment of non-infectious uveitis, cutaneous sarcoidosis
and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting
FcRn in development across several IgG-mediated autoimmune indications; and
mosliciguat, an inhaled sGC activator in development for pulmonary hypertension
associated with interstitial lung disease. We advance our pipeline by creating
nimble subsidiaries or “Vants” to develop and commercialize our medicines and
technologies. For more information, visit www.roivant.com.
                                                                                
  Roivant Forward-Looking Statements                                            
                                                                                
This press release contains forward-looking statements. Statements in this press
release may include statements that are not historical facts and are considered
forward-looking within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), which are usually identified by
the use of words such as “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and variations of such
words or similar expressions. The words may identify forward-looking statements,
but the absence of these words does not mean that a statement is not forward-
looking. We intend these forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements
regarding our or our management team’s expectations, hopes, beliefs, intentions
or strategies regarding the future, and statements that are not historical
facts, including statements about the clinical and therapeutic potential of our
product and product candidates, the availability and success of topline results
from our ongoing clinical trials, the timing of potential regulatory approvals
for our product and product candidates, any commercial potential of our product
and product candidates following applicable regulatory approvals and the outcome
of any pending litigation. In addition, any statements that refer to
projections, forecasts or other characterizations of future events, results or
circumstances, including any underlying assumptions, are forward-looking
statements. Actual results may differ materially from those contemplated in
these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as
reflected in or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or strategies
will be attained or achieved. Furthermore, actual results may differ materially
from those described in the forward-looking statements and will be affected by a
number of risks, uncertainties and assumptions, including, but not limited to,
those risks set forth in the Risk Factors section of our filings with the U.S.
Securities and Exchange Commission. Moreover, we operate in a very competitive
and rapidly changing environment in which new risks emerge from time to time.
These forward-looking statements are based upon the current expectations and
beliefs of our management as of the date of this press release, and are subject
to certain risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Except as
required by applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contacts:

Investors

Keyur Parekh

[email protected]

Media

Stephanie Lee

[email protected]

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.